Vascular endothelial growth factor (VEGF)-D is a member of the VEGF family of angiogenic growth factors that recognizes and activates the vascular endothelial growth factor receptor (VEGFR)
During endochondral bone formation, mesenchymal cells differentiate into chondrocytes, which secrete a cartilage template. Chondrocytes in the centers of the cartilage templates become hypertrophic and produce Vascular endothelial growth factor (VEGF) that stimulates vascular invasion of the cartilage template. Upon this process, the hypertrophic chondrocytes die through apoptosis and are replaced by osteoblasts brought in from the bone collar (1, 2) . The interplay between chondrocytes and osteoblasts at the growth plate determines the longitudinal growth of long bones. Osteoblasts are responsible for matrix deposition and bone mineralization. Early during their differentiation, osteoblasts express RUNX2 (also known as CBFA1), which is held inactive by Twist proteins (3) . Later, osteoblasts express the specific marker osteocalcin, which is required for bone mineralization (4) . Several growth factors expressed in the growth plate including Epidermal growth factor, members of Fibroblast growth factor family, Insulin growth factor-1, Platelet growth factor, members of Transforming growth factor-β family, Indian hedgehog, and VEGF are involved in cell proliferation, and differentiation during bone formation (1, 2, 5) . Among these VEGF has been shown to play a critical role. VEGF was first identified as an angiogenic factor that is expressed in different splicing forms. It binds and activates VEGFR-1 (also known as Flt-1) and VEGFR-2 (also known as KDR or Flk1) on endothelial cells and their expression is required for vascular development and adult angiogenesis (6, 7) . During skeletal development VEGF has been shown to play a role in blood vessel invasion that is essential for coupling resorption of cartilage with mineralization of the extracellular matrix and bone formation (8) (9) (10) and synergizes with BMP2 to promote bone formation and bone healing via modulation of angiogenesis (11) . VEGF is essential not only for normal angiogenesis, but also to allow normal differentiation of hypertrophic chondrocytes, osteoblasts, and osteoclasts (5, (12) (13) (14) (15) (16) (17) (18) . VEGF plays a role in bone repair. In mouse femur fractures treatment with exogenous VEGF enhanced not only blood vessel formation, but also ossification and new bone maturation, while VEGF inhibition decreased bone formation and callus mineralization (19) . Although experiments in osteoblasts demonstrated an increase of cell migration in response to VEGF (14) , no functional data of the activity of VEGFRs in osteoblasts has been reported. During mouse development, the expression of another member of the VEGF family, VEGF-D, was detected in the periosteum/osteoblast layer of the developing vertebral column, the limb buds, and the dental mesenchyme close to the enamel epithelium (20) . As in mouse VEGF-D only recognizes murine VEGFR-3 (21) its pattern of expression suggests that VEGF-D/VEGFR-3 signaling plays a role in bone development. VEGFR-3 has been previously shown to be involved in vascular development, lymphatic maintenance and tumor angiogenesis (22) (23) (24) (25) (26) (27) (28) . Here we investigated the involvement of the angiogenic growth factor VEGF-D and its receptor VEGFR-3 in osteoblasts. We show that osteoblasts of the long bones of newborn mice and primary human osteoblasts express VEGFR-3. Osteoblasts treated with recombinant VEGF-D respond with VEGFR-3 auto-phopshorylation, osteocalcin expression and nodule formation. Moreover, VEGF treatment induces VEGF-D expression in these cells. Accordingly, the inactivation of VEGF-D activity by neutralizing antibodies or VEGFR-3 silencing inhibited both VEGF-and VEGF-D-dependent nodule formation in osteoblasts. Our data demonstrate the involvement of VEGF-D in maturation and regulation of osteoblastic activity via VEGFR-3.
EXPERIMENTAL PROCEDURES
Primary Human Osteoblast Cultures -Bone samples were obtained from 10 women and 4 men (aged 56-78 years, with a mean age of 66 years) who underwent total hip replacement surgery for degenerative joint disease. After extensive washes of trabecular bone explants, small bone chips were placed in flasks with Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% heatinactivated fetal bovine serum (Life Technologies, Inc.), 2 mM L-glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin. Cultures were incubated at 37° C in a humidified, 5% CO 2 atmosphere. For differentiation assays, osteoblasts were seeded in 6-well plates. Upon confluence, recombinant human VEGF-D (0-50 ng/ml) with or without the mouse monoclonal anti-human VEGF-D neutralizing antibody (MAb 3.11A25) at a concentration of 5-36 µg/ml were added. Media were changed every two days. The mineralized nodule formation was determined after 15 days by using Alizarin Red S staining as previously described (29) . Immunofluorescent Microscopy -For histological analysis, newborn SWISS mice were sacrificed and limbs were dissected and embedded in OCT (Tissue-Tek ® ). 10 µ m cryostat sections were cut and fixed in 3% paraformaldehyde for 20 min at room temperature. Human osteoblasts were grown on glass coverslips and, after treatment, fixed in 3% paraformaldehyde for 15 min at room temperature. For permeabilization, cryostat sections were incubated with 0.5% Triton X-100 in PBS for 5 min at 4° C. For the staining of cultured human osteoblasts cells were not permeabilized. Specimens were washed twice in PBS, blocked with 1% bovine serum albumin (BSA) in PBS for 1 h at room temperature, and incubated for 1 h at 37° C with the following primary antibodies: rabbit polyclonal anti-VEGF-D (30), goat polyclonal anti-PECAM-1 (Santa Cruz Biotechnology), rat monoclonal anti-VEGFR-3 (eBioscence), goat polyclonal anti-osteocalcin (Santa Cruz Biotechnology), and goat polyclonal anti-VEGFR-3 (R&D Systems), diluted in 1% BSA/PBS. After washing, specimens were incubated for 1 h at 37° C with Alexa Fluor-568 or Alexa Fluor-488 secondary antibodies (Molecular Probes), and mounted in Mowiol 4-88 (Calbiochem). Fluorescent images were captured using a Leica TCS SP2 laser scanning confocal microscope. Tris-(2-carboxyethyl)phosphine-HCl using an AKTA purifier (Amersham Biosciences). To obtain a VEGF-D dimer, the monomer (0,25 mg/ml) was dialyzed against: a) 6 M Urea, 0.1 M NaH 2 PO 4 , 10 mM Tris-HCl, 5 mM GSH, pH 8.5; b) 50 mM Tris-HCl, 5 mM NaCl, 0.5 M LArginine, 5 mM GSH, 1 mM GSSG, 2 M Urea, pH 8.5; c) in the same buffer as b without 2 M Urea; d) 50 mM Tris-HCl, pH8. Each dialysis was performed for 16 h. To eliminate aggregate forms, VEGF-D was loaded onto a His-TRAP affinity column in non-denaturing conditions and eluted with 250 mM imidazole. Imidazole was removed on a HiTrap desalting column and the dimer formation was checked by gel filtration using a Superdex 75 HR Column. All the columns were from Amersham Biosciences.
Monoclonal Antibody Production and
Characterization -Monoclonal antibodies (MAbs) against human recombinant VEGF-D were generated using a standard fusion protocol (32) . Hybridomas were screened by enzyme-linked immunosorbent assay (ELISA). Antibody-secreting hybridomas were cloned and inoculated into pristane-primed BALB/c mice for production of ascitic fluid. The isotypes were determined using the Mouse monoclonal antibody isotyping kit (Amersham Biosciences). Antibodies were purified by affinity chromatography and characterized by immunoprecipitation and cell proliferation assays. Cell proliferation and viability assaysHuman umbilical vein endothelial cells (HUVEC) were grown in M199 culture medium containing 20% fetal bovine serum and growth supplements. 5 x 10 3 cells were plated in a 96-well plate and starved for 24 h in DMEM containing 2% fetal bovine serum and 1% BSA. Cells were treated with 25 ng/ml VEGF-D in the presence of different concentrations of an anti-VEGF-D monoclonal antibody, and 0.5 µCi/well [methylthymidine uptake by a β-counter. The assays for cell viability were performed by using thiazolyl blue tetrazolium bromide (MTT, Sigma Chemical) according to manufacturer's instructions.
Immunoprecipitation and Immunoblotting
Assays -For osteoblast immunoprecipitation analysis, cultures were starved in serum-free DMEM containing 1% BSA for 24 h. Before stimulation, cells were incubated with 0.1 mM Na 3 VO 4 for 10 min to inhibit phosphatase activity. Cells were stimulated for 30 min with 25 ng/ml VEGF-D at 37°C, washed with icecold PBS containing 0.1 mM Na 3 VO 4 , and lysed in 1 ml of lysis buffer (50 mM Hepes, pH 7.4, 150 mM NaCl, 1% Triton-X 100, 1.5 mM MgCl 2 , 1mM EGTA, 10mM NaH 2 PO 4 , 100 mM NaF, 10 mM DTT, 1 mM Na 3 VO 4 , protease inhibitors, Sigma Chemical). Cells lysates were incubated on ice for 10 min, centrifuged at 10,000 x g for 15 min, and the supernatants were incubated with anti-VEGFR-3 antibodies. For immunoprecipitation analysis of VEGF family growth factors, HEK293 stable clones expressing human VEGF 164 , VEGF-C, and VEGF-D were generated (M. B. unpublished data). 400 µl of supernatant from serum starved cells were immunoprecipitated with 2 µg of MAb 3.11A25 in 50 mM Tris-Hcl pH 7.5, 150 mM NaCl, 0.5% Nonidet P40.
Immunoprecipitates were analysed by 6-15% SDS-PAGE. Immunoblot analysis were performed as previously described (33) . The following primary antibodies were used: mouse monoclonal anti-VEGFR-3, anti-P-Y, anti-VEGF, and anti-β-tubulin (Santa Cruz Biotechnology); anti-P-p44 MAPK and antip44/42 MAPK (Cell Signaling); anti-VEGF-C (R&D Systems); anti-VEGF-D (MAb 197). The blots were washed, incubated with HRPlabeled secondary antibodies and developed by using the enhanced chemiluminescence substrate (Amersham Bioscience). VEGFR-3 RNA Interference -Small hairpin (shRNA) cassette was cloned and the recombinant lentiviruses were produced as previously described (34) .
Briefly, oligonucleotides coding for human VEGFR-3 and unrelated shRNA were designed to contain a s e n s e s t r a n d
F c l o n e ) , a n d 5 ' -GCCACAAGTTCAGCGTGTC-3' (unrelated) followed by a spacer (5'-TTCAAGAGA-3') and their reverse complementary strand followed by 5 thymidines as an RNA polymerase III transcriptional stop signal. The complementary oligonucleotides were phosphorylated, annealed, and cloned into lentiviral vector. HEK293 cells were transiently transfected using PolyFect transfection reagent (Qiagen) according to the manufacturer instructions. The lentiviruses were harvested 24 and 48 h later and filtered through 0.22-µm pore cellulose acetate filters. Recombinant lentiviruses were concentrated by ultracentrifugation for 2 hours at 50,000 x g. Vector infectivity was evaluated by infecting cells with a GFP vector and titrating shRNAexpressing virus by real-time quantitative RT-PCR of a common lentiviral genome region compared with the GFP vector. Real-time quantitative RT-PCR analysis -Total RNA was isolated from cells by the guanidinium thiocyanate method, quantified, and integrity was tested by gel electrophoresis. The gene expression analysis was performed using a LightCycler apparatus, and data were analyzed with the LightCycler software version 3.5 (Roche Applied Science). The RT-PCR reactions were set up in microcapillary tubes using the LightCycler RNA Amplification Kit SYBR Green I (Roche Applied Science) following the manufacturer's instructions. For each sample, triplicate determinations were made, and the gene expression was normalized to the amount of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) on the same sample. The primer pairs used are reported in Table I . (Fig.1 C) . To verify whether VEGF-D expression was compatible with a role in bone formation, we analyzed the expression of its receptor VEGFR-3, as in mouse VEGF-D only recognizes VEGFR-3 (21). VEGFR-3 showed expression in the growth plate at the interface between the forming bone and the terminal hypertrophic chondrocytes (Fig. 1 ). This is a bone developing region characterized by new blood vessel formation and differentiating osteoblasts. VEGFR-3 is transiently expressed in endothelial cells during active angiogenesis (22, 27, 35) . Consistent with this, we observed low levels of VEGFR-3 expression in endothelial cells in the radius of new born mice, reflecting the fact that a peak of angiogenesis in the growing bone takes place before birth. Double staining between VEGFR-3 and PECAM1 (CD31), a marker of endothelial cells, revealed a partial overlapping of these signals demonstrating that VEGFR-3 is still expressed in endothelial cells at this stage (Fig. 1 D-F) . A more consistent VEGFR-3 signal was observed in osteocalcin positive cells (Fig. 1, G-L ). These data demonstrate that VEGFR-3 is expressed in mouse osteoblasts. VEGF-D activates VEGFR-3 on primary human osteoblasts -To address whether VEGF-D/VEGFR-3 signaling plays a functional role in osteoblasts, we obtained from trabecular bone explants primary human osteoblasts and analyzed VEGF-D response on these cells. We detected VEGFR-3 expression in primary human osteoblasts by immunofluorescence analysis and by Western blot (Fig. 2 A-D) , while we could not detect VEGFR-2 in these cells or VEGFR-3 in fibroblasts (data not shown). To analyze VEGFR-3 auto-phosphorylation, human osteoblasts were treated with recombinant VEGF-D and whole cell lysates were immunoprecipitated with an antibody recognizing VEGFR-3 C-terminus and immunoblotted with anti-phophotyrosine antibodies. This analysis revealed that VEGF-D treatment induced VEGFR-3 autophosphorylation in osteoblasts (Fig. 2 E) . VEGFR-3 activation was leading to an intracellular signaling cascade as we observed that VEGF-D treatment was followed by an increase of the phosphorylation of the intracellular protein ERK1/2 (Fig. 2 E) . These experiments demonstrate that VEGF-D recognizes and activates VEGFR-3 expressed in primary human osteoblasts. VEGF-D induces nodule formation and osteocalcin expression -To investigate whether VEGF-D affects osteoblast differentiation, primary human osteoblasts were grown in complete medium for 14 days in the presence of different concentrations of VEGF-D. As shown in Figure 3 , VEGF-D significantly increased the number of mineralized nodules in a dose-dependent manner (Fig. 3 A) . In addition, the nodules grew bigger and better mineralized than those of the control cultures that showed less and poorly mineralized nodules (Fig. 3 B) . To verify whether the neutralization of VEGF-D activity affects osteoblast differentiation, we used the MAb 3.11A25 (isotype IgG2a) able to selectively immunoprecipitate VEGF-D (Fig. 3  C) , and to inhibit VEGF-D-dependent proliferation of endothelial cells (Fig. 3 D) . The treatment of osteoblast cultures with MAb 3.11.A25 decreased nodule formation to values of untreated cells while a non correlated antibody did not influence nodule formation even at high concentrations (Fig. 3 E) . Importantly, the treatment of osteoblasts for 14 days with high concentrations of MAb 3.11A25 did not alter osteoblasts viability ( 
F).
Taken together these data demonstrated that VEGF-D induces osteoblasts to form mineralization nodules. Quantitative real-time RT-PCR analysis of the expression of RUNX2, a marker of early differentiation of osteoblast, and osteocalcin, a marker of late osteoblast differentiation, showed that VEGF-D treatment did not influence RUNX2 expression, while osteocalcin mRNA was significantly increased in a dose-dependent manner (Fig. 4 A) . Moreover, osteocalcin induction was inhibited by the anti-VEGF-D neutralizing antibody (Fig. 4 B) . Immunofluorescence analysis also showed that VEGF-D treatment increased osteocalcin secretion with respect to untreated cells (Fig. 4 C-F) demonstrating that VEGF-D plays a role in osteoblast differentiation.
Inhibition of VEGFR-3 signaling reduces nodule formation -To investigate whether VEGF-D-dependent osteoblast differentiation
acts via VEGFR-3 signaling, we generated two lentiviral vectors (clones D and F) expressing small hairpin RNA (shRNA) designed to inhibit VEGFR-3. Primary human osteoblasts infected with either lentivirus expressing VEGFR-3 shRNA, but not an unrelated shRNA, showed a reduced VEGFR-3 protein expression and affected VEGF-D-dependent ERK1/2 activation (Fig. 5 A) . Osteoblasts knockdown for VEGFR-3, showed significant impairment of nodule formation and osteocalcin production following VEGF-D treatment (Fig. 5 B, C) . As VEGF plays a direct role in osteoblast migration, probably via the activation of VEGFR-1 (14) , to provide a functional link between VEGF and VEGF-D-dependent osteoblast differentiation, we analyzed whether in osteoblasts VEGF-D expression depends on VEGF signaling. Quantitative real-time RT-PCR analysis revealed that, following VEGF treatment, osteoblasts responded with an increased expression of VEGF-D, demonstrating that in osteoblasts VEGF-D expression is under the control of VEGF (Fig.  6 A) . To analyze whether VEGF-D plays a role in VEGF-dependent osteoblast differentiation, we treated osteoblasts with VEGF in the presence of the monoclonal antibody inhibiting VEGF-D activity and measured the nodule formation induced by VEGF. VEGF treatment of primary human osteoblasts induced a significant number of mineralization nodules. The pretreatment of these cultures with VEGF-D neutralizing antibodies efficiently inhibited VEGF-dependent nodule formation (Fig. 6 B) . This inhibition affected specifically the VEGFR-3 signaling, as we also observed inhibition of VEGF-dependent nodules formation in cells silenced for VEGFR-3 ( 
V E G F -D
i n d u c e s a n g i o g e n e s i s , lymphangiogenesis as well as metastatic spread of tumors via lymphatic vessels activating VEGFR-3 on vascular and lymphatic endothelial cells (30, 36, 37) . Besides playing a role in lymphatic vessels homeostasis, VEGFR-3 is implicated in the remodeling of the primary vascular network, and in reorganizing the integrity of endothelial vessels during angiogenesis (22, (25) (26) (27) . On endothelial cells, VEGFR-3 signaling activates proliferation, migration, and survival (38) . The data presented in this report demonstrate that, in addition to play a biological function in endothelial cells, VEGF-D/VEGFR-3 signaling is also implicated in osteoblast differentiation. Expression analysis on primary human osteoblasts demonstrated that VEGF-D induces the expression of osteocalcin, a late marker of differentiation, while it has no effect on the early marker RUNX2. RT-PCR analysis in these cells revealed that the inhibitors of RUNX2, Twist 1 and 2 expressed early during osteoblasts differentiation (3), are already down-regulated in osteoblasts before VEGF-D treatment (MO unpublished observation). These data therefore suggest that VEGF-D/VEGFR-3 signaling is not involved in the activation of RUNX2 function, but must be involved in the activation of other yetunknown regulator(s) of osteoblast differentiation which act at a later stage of osteoblast maturation. This is also confirmed by the fact that VEGF-D induced mineralization in these cells. Hypertrophic chondrocytes secrete a number of growth factors including VEGF, which orchestrate blood vessel formation, chondrocyte maturation, the differentiation of osteoblasts forming the mineralized bone collar as well as the recruitment of osteoclasts into hypertrophic cartilage (16) (and reference therein). In line with these experiments, our results are consistent with a model in which VEGF acts early on bone differentiation by inducing vessel formation, osteoblasts recruitment to the growth plate, and also stimulating VEGF-D production in osteoblasts. VEGF-D in turn acts as a downstream effector of VEGF with autocrine activity on osteoblasts. Therefore these two factors contribute to the process of timely coordinated osteoblast differentiation. These results also imply that VEGF, probably acting on VEGFR-1, stimulates a different cellular response than VEGF-D acting on VEGFR-3. A similar conclusion was previously reached by the analysis of sinusoidal endothelial cells were VEGFR-1 induced these cells to produce the hepatocyte growth factor, while VEGFR-2 induced their proliferation (39) . Further analysis of the downstream signaling from these two receptors might enlighten the physiological differences between these two receptors in osteoblasts.
Our data suggest that VEGF-D plays a role in the development of long bones. During mouse development VEGF-D expression was also detected in the periosteum layer of the developing vertebral column and in the dental mesenchyme close to the enamel epithelium where dentin and enamel matrices are deposited (20) , suggesting that VEGF-D might also play a role in intramembranous bone formation.
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